CDC: Self-administered subcutaneous DMPA should be made available
Ontario resuming use of AstraZeneca, but only as second dose
21 May 2021Providing medications for free leads to greater adherence and cost-savings, study shows
21 May 2021CDC: Self-administered subcutaneous DMPA should be made available
(HealthDay)—Self-administered subcutaneous depot medroxyprogesterone acetate (DMPA-SC) should be made available as an additional approach for contraception, according to research published in the May 21 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
